New antiviral drugs, vaccines and classic public health interventions against SARS coronavirus.
Identifieur interne : 000E04 ( Ncbi/Checkpoint ); précédent : 000E03; suivant : 000E05New antiviral drugs, vaccines and classic public health interventions against SARS coronavirus.
Auteurs : John S. Oxford [Royaume-Uni] ; Shobana Balasingam ; Charlotte Chan ; Andrew Catchpole ; Robert LambkinSource :
- Antiviral chemistry & chemotherapy [ 0956-3202 ] ; 2005.
Descripteurs français
- KwdFr :
- Animaux, Antiviraux (usage thérapeutique), Asie, Cellules Vero, Chats, Humains, Phylogénie, Rats, Ribavirine (usage thérapeutique), Santé publique, Syndrome respiratoire aigu sévère (traitement médicamenteux), Syndrome respiratoire aigu sévère (virologie), Vaccins antiviraux (immunologie), Vaccins antiviraux (usage thérapeutique), Virus du SRAS (), Virus du SRAS (pathogénicité).
- MESH :
- immunologie : Vaccins antiviraux.
- pathogénicité : Virus du SRAS.
- traitement médicamenteux : Syndrome respiratoire aigu sévère.
- usage thérapeutique : Antiviraux, Ribavirine, Vaccins antiviraux.
- virologie : Syndrome respiratoire aigu sévère.
- Animaux, Asie, Cellules Vero, Chats, Humains, Phylogénie, Rats, Santé publique, Virus du SRAS.
English descriptors
- KwdEn :
- Animals, Antiviral Agents (therapeutic use), Asia, Cats, Chlorocebus aethiops, Humans, Phylogeny, Public Health, Rats, Ribavirin (therapeutic use), SARS Virus (classification), SARS Virus (drug effects), SARS Virus (pathogenicity), Severe Acute Respiratory Syndrome (drug therapy), Severe Acute Respiratory Syndrome (virology), Vero Cells, Viral Vaccines (immunology), Viral Vaccines (therapeutic use).
- MESH :
- chemical , immunology : Viral Vaccines.
- chemical , therapeutic use : Antiviral Agents, Ribavirin, Viral Vaccines.
- geographic : Asia.
- classification : SARS Virus.
- drug effects : SARS Virus.
- drug therapy : Severe Acute Respiratory Syndrome.
- pathogenicity : SARS Virus.
- virology : Severe Acute Respiratory Syndrome.
- Animals, Cats, Chlorocebus aethiops, Humans, Phylogeny, Public Health, Rats, Vero Cells.
Abstract
Severe acute respiratory syndrome (SARS) is caused by one of two recently discovered coronaviruses. The virus is emergent from South East (SE) Asian mammals: either the civet cat, a related species or a rat species. The virus has a long incubation period and low reproduction number (R0 value) and hence the first outbreak in 2004 was controlled by hygiene and quarantine. However, the healthcare system was compromised and the economic cost was extremely high. Fortunately, the virus is easily cultivated in Vero E6 cells and therefore the search for new antivirals and vaccines was initiated within weeks of the discovery of the virus using classic techniques of cell culture and electron microscopy. Molecular diagnostics facilitated rapid and accurate diagnosis, a key factor in containing the outbreak. The broad-spectrum molecule ribavirin was used in SE Asia in infected patients alongside corticosteroids. In retrospect, many patients survived due to careful nursing. The only currently accepted intervention is interferon. Coronavirus replicon systems should facilitate rapid screening of new inhibitors and the complex mechanism of viral replication will ensure that drugs are developed against at least five molecular targets, in particular the viral protease.
DOI: 10.1177/095632020501600102
PubMed: 15739618
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 002868
- to stream PubMed, to step Curation: 002868
- to stream PubMed, to step Checkpoint: 002604
- to stream Ncbi, to step Merge: 000E04
- to stream Ncbi, to step Curation: 000E04
Links to Exploration step
pubmed:15739618Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">New antiviral drugs, vaccines and classic public health interventions against SARS coronavirus.</title><author><name sortKey="Oxford, John S" sort="Oxford, John S" uniqKey="Oxford J" first="John S" last="Oxford">John S. Oxford</name><affiliation wicri:level="1"><nlm:affiliation>Retroscreen Virology Ltd, Centre for Infectious Diseases, Barts, UK. j.oxford@retroscreen.com</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Retroscreen Virology Ltd, Centre for Infectious Diseases, Barts</wicri:regionArea><wicri:noRegion>Barts</wicri:noRegion></affiliation></author><author><name sortKey="Balasingam, Shobana" sort="Balasingam, Shobana" uniqKey="Balasingam S" first="Shobana" last="Balasingam">Shobana Balasingam</name></author><author><name sortKey="Chan, Charlotte" sort="Chan, Charlotte" uniqKey="Chan C" first="Charlotte" last="Chan">Charlotte Chan</name></author><author><name sortKey="Catchpole, Andrew" sort="Catchpole, Andrew" uniqKey="Catchpole A" first="Andrew" last="Catchpole">Andrew Catchpole</name></author><author><name sortKey="Lambkin, Robert" sort="Lambkin, Robert" uniqKey="Lambkin R" first="Robert" last="Lambkin">Robert Lambkin</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2005">2005</date><idno type="RBID">pubmed:15739618</idno><idno type="pmid">15739618</idno><idno type="doi">10.1177/095632020501600102</idno><idno type="wicri:Area/PubMed/Corpus">002868</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002868</idno><idno type="wicri:Area/PubMed/Curation">002868</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002868</idno><idno type="wicri:Area/PubMed/Checkpoint">002604</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002604</idno><idno type="wicri:Area/Ncbi/Merge">000E04</idno><idno type="wicri:Area/Ncbi/Curation">000E04</idno><idno type="wicri:Area/Ncbi/Checkpoint">000E04</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">New antiviral drugs, vaccines and classic public health interventions against SARS coronavirus.</title><author><name sortKey="Oxford, John S" sort="Oxford, John S" uniqKey="Oxford J" first="John S" last="Oxford">John S. Oxford</name><affiliation wicri:level="1"><nlm:affiliation>Retroscreen Virology Ltd, Centre for Infectious Diseases, Barts, UK. j.oxford@retroscreen.com</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Retroscreen Virology Ltd, Centre for Infectious Diseases, Barts</wicri:regionArea><wicri:noRegion>Barts</wicri:noRegion></affiliation></author><author><name sortKey="Balasingam, Shobana" sort="Balasingam, Shobana" uniqKey="Balasingam S" first="Shobana" last="Balasingam">Shobana Balasingam</name></author><author><name sortKey="Chan, Charlotte" sort="Chan, Charlotte" uniqKey="Chan C" first="Charlotte" last="Chan">Charlotte Chan</name></author><author><name sortKey="Catchpole, Andrew" sort="Catchpole, Andrew" uniqKey="Catchpole A" first="Andrew" last="Catchpole">Andrew Catchpole</name></author><author><name sortKey="Lambkin, Robert" sort="Lambkin, Robert" uniqKey="Lambkin R" first="Robert" last="Lambkin">Robert Lambkin</name></author></analytic><series><title level="j">Antiviral chemistry & chemotherapy</title><idno type="ISSN">0956-3202</idno><imprint><date when="2005" type="published">2005</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antiviral Agents (therapeutic use)</term><term>Asia</term><term>Cats</term><term>Chlorocebus aethiops</term><term>Humans</term><term>Phylogeny</term><term>Public Health</term><term>Rats</term><term>Ribavirin (therapeutic use)</term><term>SARS Virus (classification)</term><term>SARS Virus (drug effects)</term><term>SARS Virus (pathogenicity)</term><term>Severe Acute Respiratory Syndrome (drug therapy)</term><term>Severe Acute Respiratory Syndrome (virology)</term><term>Vero Cells</term><term>Viral Vaccines (immunology)</term><term>Viral Vaccines (therapeutic use)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term><term>Antiviraux (usage thérapeutique)</term><term>Asie</term><term>Cellules Vero</term><term>Chats</term><term>Humains</term><term>Phylogénie</term><term>Rats</term><term>Ribavirine (usage thérapeutique)</term><term>Santé publique</term><term>Syndrome respiratoire aigu sévère (traitement médicamenteux)</term><term>Syndrome respiratoire aigu sévère (virologie)</term><term>Vaccins antiviraux (immunologie)</term><term>Vaccins antiviraux (usage thérapeutique)</term><term>Virus du SRAS ()</term><term>Virus du SRAS (pathogénicité)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Viral Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term><term>Ribavirin</term><term>Viral Vaccines</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>Asia</term></keywords><keywords scheme="MESH" qualifier="classification" xml:lang="en"><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Vaccins antiviraux</term></keywords><keywords scheme="MESH" qualifier="pathogenicity" xml:lang="en"><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="pathogénicité" xml:lang="fr"><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Syndrome respiratoire aigu sévère</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antiviraux</term><term>Ribavirine</term><term>Vaccins antiviraux</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Syndrome respiratoire aigu sévère</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Cats</term><term>Chlorocebus aethiops</term><term>Humans</term><term>Phylogeny</term><term>Public Health</term><term>Rats</term><term>Vero Cells</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Asie</term><term>Cellules Vero</term><term>Chats</term><term>Humains</term><term>Phylogénie</term><term>Rats</term><term>Santé publique</term><term>Virus du SRAS</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Severe acute respiratory syndrome (SARS) is caused by one of two recently discovered coronaviruses. The virus is emergent from South East (SE) Asian mammals: either the civet cat, a related species or a rat species. The virus has a long incubation period and low reproduction number (R0 value) and hence the first outbreak in 2004 was controlled by hygiene and quarantine. However, the healthcare system was compromised and the economic cost was extremely high. Fortunately, the virus is easily cultivated in Vero E6 cells and therefore the search for new antivirals and vaccines was initiated within weeks of the discovery of the virus using classic techniques of cell culture and electron microscopy. Molecular diagnostics facilitated rapid and accurate diagnosis, a key factor in containing the outbreak. The broad-spectrum molecule ribavirin was used in SE Asia in infected patients alongside corticosteroids. In retrospect, many patients survived due to careful nursing. The only currently accepted intervention is interferon. Coronavirus replicon systems should facilitate rapid screening of new inhibitors and the complex mechanism of viral replication will ensure that drugs are developed against at least five molecular targets, in particular the viral protease.</div></front></TEI><affiliations><list><country><li>Royaume-Uni</li></country></list><tree><noCountry><name sortKey="Balasingam, Shobana" sort="Balasingam, Shobana" uniqKey="Balasingam S" first="Shobana" last="Balasingam">Shobana Balasingam</name><name sortKey="Catchpole, Andrew" sort="Catchpole, Andrew" uniqKey="Catchpole A" first="Andrew" last="Catchpole">Andrew Catchpole</name><name sortKey="Chan, Charlotte" sort="Chan, Charlotte" uniqKey="Chan C" first="Charlotte" last="Chan">Charlotte Chan</name><name sortKey="Lambkin, Robert" sort="Lambkin, Robert" uniqKey="Lambkin R" first="Robert" last="Lambkin">Robert Lambkin</name></noCountry><country name="Royaume-Uni"><noRegion><name sortKey="Oxford, John S" sort="Oxford, John S" uniqKey="Oxford J" first="John S" last="Oxford">John S. Oxford</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Ncbi/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000E04 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd -nk 000E04 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Ncbi
|étape= Checkpoint
|type= RBID
|clé= pubmed:15739618
|texte= New antiviral drugs, vaccines and classic public health interventions against SARS coronavirus.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/RBID.i -Sk "pubmed:15739618" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |